These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20598131)

  • 1. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
    Cocco E; Casagrande F; Bellone S; Richter CE; Bellone M; Todeschini P; Holmberg JC; Fu HH; Montagna MK; Mor G; Schwartz PE; Arin-Silasi D; Azoudi M; Rutherford TJ; Abu-Khalaf M; Pecorelli S; Santin AD
    BMC Cancer; 2010 Jul; 10():349. PubMed ID: 20598131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
    Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
    Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
    Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Casagrande F; Cocco E; Bellone S; Richter CE; Bellone M; Todeschini P; Siegel E; Varughese J; Arin-Silasi D; Azodi M; Rutherford TJ; Pecorelli S; Schwartz PE; Santin AD
    Cancer; 2011 Dec; 117(24):5519-28. PubMed ID: 21692061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.
    Cocco E; Shapiro EM; Gasparrini S; Lopez S; Schwab CL; Bellone S; Bortolomai I; Sumi NJ; Bonazzoli E; Nicoletti R; Deng Y; Saltzman WM; Zeiss CJ; Centritto F; Black JD; Silasi DA; Ratner E; Azodi M; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Int J Cancer; 2015 Dec; 137(11):2618-29. PubMed ID: 26060989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity of Clostridium perfringens enterotoxin depends on the conditions of claudin-4 in ovarian carcinoma cells.
    Tanaka S; Aoyama T; Ogawa M; Takasawa A; Murata M; Osanai M; Saito T; Sawada N
    Exp Cell Res; 2018 Oct; 371(1):278-286. PubMed ID: 30142326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
    Yuan X; Lin X; Manorek G; Kanatani I; Cheung LH; Rosenblum MG; Howell SB
    Mol Cancer Ther; 2009 Jul; 8(7):1906-15. PubMed ID: 19567823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.
    Cocco E; Deng Y; Shapiro EM; Bortolomai I; Lopez S; Lin K; Bellone S; Cui J; Menderes G; Black JD; Schwab CL; Bonazzoli E; Yang F; Predolini F; Zammataro L; Altwerger G; de Haydu C; Clark M; Alvarenga J; Ratner E; Azodi M; Silasi DA; Schwartz PE; Litkouhi B; Saltzman WM; Santin AD
    Mol Cancer Ther; 2017 Feb; 16(2):323-333. PubMed ID: 27956521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.
    Litkouhi B; Kwong J; Lo CM; Smedley JG; McClane BA; Aponte M; Gao Z; Sarno JL; Hinners J; Welch WR; Berkowitz RS; Mok SC; Garner EI
    Neoplasia; 2007 Apr; 9(4):304-14. PubMed ID: 17460774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
    Gao Z; Xu X; McClane B; Zeng Q; Litkouhi B; Welch WR; Berkowitz RS; Mok SC; Garner EI
    Clin Cancer Res; 2011 Mar; 17(5):1065-74. PubMed ID: 21123456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.
    Long H; Crean CD; Lee WH; Cummings OW; Gabig TG
    Cancer Res; 2001 Nov; 61(21):7878-81. PubMed ID: 11691807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
    Gabig TG; Waltzer WC; Whyard T; Romanov V
    Biochem Biophys Res Commun; 2016 Sep; 478(2):887-92. PubMed ID: 27520378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue distribution and safety evaluation of a claudin-targeting molecule, the C-terminal fragment of Clostridium perfringens enterotoxin.
    Li X; Saeki R; Watari A; Yagi K; Kondoh M
    Eur J Pharm Sci; 2014 Feb; 52():132-7. PubMed ID: 24231339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.
    Michl P; Buchholz M; Rolke M; Kunsch S; Löhr M; McClane B; Tsukita S; Leder G; Adler G; Gress TM
    Gastroenterology; 2001 Sep; 121(3):678-84. PubMed ID: 11522752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
    Pahle J; Menzel L; Niesler N; Kobelt D; Aumann J; Rivera M; Walther W
    BMC Cancer; 2017 Feb; 17(1):129. PubMed ID: 28193196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin.
    Ebihara C; Kondoh M; Hasuike N; Harada M; Mizuguchi H; Horiguchi Y; Fujii M; Watanabe Y
    J Pharmacol Exp Ther; 2006 Jan; 316(1):255-60. PubMed ID: 16183701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy.
    English DP; Santin AD
    Int J Mol Sci; 2013 May; 14(5):10412-37. PubMed ID: 23685873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin.
    Katahira J; Inoue N; Horiguchi Y; Matsuda M; Sugimoto N
    J Cell Biol; 1997 Mar; 136(6):1239-47. PubMed ID: 9087440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.
    Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S
    Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.